Education and Training
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
This phase II trial studies how well giving brentuximab vedotin together with combination chemotherapy works in treating older patients with previously untreated stage II-IV Hodgkin lymphoma (HL). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine (AVD), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin, doxorubicin hydrochloride, vinblastine, and dacarbazine together may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: brentuximab vedotin
- drug: doxorubicin hydrochloride
- drug: vinblastine
- drug: dacarbazine
- procedure: quality-of-life assessment
- genetic: DNA analysis
- genetic: RNA analysis
- radiation: fludeoxyglucose F 18
- procedure: positron emission tomography
- other: laboratory biomarker analysis
- other: immunohistochemistry staining method
- genetic: polymorphism analysis
Eligibility
Inclusion Criteria:
- Voluntary written informed consent before performance of any study-related procedure
not part of normal medical care, with the understanding that consent may be withdrawn
by the subject at any time without prejudice to future medical care
- Previously untreated classical Hodgkin lymphoma (i.e., nodular sclerosis, mixed
cellularity, lymphocyte depleted, lymphocyte-rich, and not otherwise specified [NOS]);
nodular lymphocyte predominant Hodgkin lymphoma is not eligible
- Stage II, III, and IV disease by Ann Arbor classification
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
- Patients must have bi-dimensional measurable disease documented in the lymphoma
baseline tumor assessment form within 30 days prior to registration (at least 1.5 cm);
patients with non-measurable disease in addition to measurable disease must have been
assessed within 60 days prior to registration
- Patients must have a bone marrow biopsy (bilateral preferred, unilateral acceptable)
within 60 days prior to registration
- Patients must have a multi gated acquisition scan (MUGA) or echocardiogram within 60
days prior to study registration and the ejection fraction must be >= 45%
- Absolute neutrophil count (ANC) > 1000/mm^3
- Platelet count > 75,000/mm^3
- Creatinine < 2.5 mg/dl
- Bilirubin < 3.0 mg/dl
- Patients with documented marrow involvement by lymphoma at the time of registration
are not required to meet the above hematologic parameters
- Patients must not have received prior chemotherapy or radiation therapy for the
treatment of Hodgkin lymphoma
- Both females and males who have partners of childbearing potential must agree to use
an effective contraceptive method during the study and for 30 days following the last
dose of study drug
- Patients must sign the informed consent form before registration
Exclusion Criteria:
- Previous treatment with brentuximab vedotin or any other prior anti-CD30-based
antibody therapy
- History of another primary malignancy that has not been in remission for at least 3
years; (the following are exempt from the 3-year limit: early stage [stage I or II]
breast cancer treated with surgery and radiation +/- hormones [without adjuvant
chemotherapy], non-melanoma skin cancer, fully excised melanoma in situ [stage 0],
curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy
or a squamous intraepithelial lesion on Papanicolaou test [PAP smear])
- Known cerebral/meningeal disease
- Any active systemic viral, bacterial, or fungal infection requiring treatment with
antimicrobial therapy within 1 week prior to first dose
- Patients with hepatitis B surface antigen (HBsAg) positive hepatitis B virus (HBV)
infection; patients with prior history of hepatitis B infection, but immune, with only
Immunoglobulin G (IgG) hepatitis core antibody + (HBcAb +) must receive anti-viral
prophylaxis (e.g., lamivudine 100mg orally [po] daily) for at least 1 week prior to
cycle 1 and throughout induction and continuation therapy and for at least 6 months
after the last brentuximab vedotin dose; in addition, consultation with a hepatologist
is recommended
- Patients with a known hypersensitivity to any excipient contained in the drug
formulation
- Patients with dementia or an altered mental state that would preclude the
understanding and rendering of informed consent
Ages Eligible for Study
60 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting